Pathological complete response to neoadjuvant systemic therapy in 789 early and locally advanced breast cancer patients: The Royal Marsden experience.
Nicolò Matteo Luca BattistiVictoria TrueNarda ChaabouniNeha ChopraKarla LeeScott ShepherdTal Shapira-RotenbergRashi JoshiSophie McGrathAlicia OkinesMarina PartonNicholas TurnerKabir MohammedMark AllenStephen JohnstonAlistair RingPublished in: Breast cancer research and treatment (2019)
In our analysis, pCR rates are consistent with the published data. Even with contemporary therapies, many patients have residual disease following NACT, suggesting a significant risk of recurrence, and may benefit from additional postoperative systemic therapy.
Keyphrases
- locally advanced
- rectal cancer
- end stage renal disease
- squamous cell carcinoma
- ejection fraction
- newly diagnosed
- chronic kidney disease
- neoadjuvant chemotherapy
- patients undergoing
- peritoneal dialysis
- radiation therapy
- systematic review
- phase ii study
- stem cells
- patient reported outcomes
- machine learning
- open label
- free survival
- real time pcr